{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T22:39:37Z","timestamp":1793659177460,"version":"4.5.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T00:00:00Z","timestamp":1600992000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T00:00:00Z","timestamp":1600992000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1007\/s12325-020-01498-5","type":"journal-article","created":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T05:02:22Z","timestamp":1601010142000},"page":"4697-4708","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":175,"title":["Effect of Empagliflozin on Liver Steatosis and Fibrosis in Patients With Non-Alcoholic Fatty Liver Disease Without Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial"],"prefix":"10.1007","volume":"37","clinical-trial-number":[{"clinical-trial-number":"irct20190122042450n1","registry":"10.18810\/irct"}],"author":[{"given":"Hoda","family":"Taheri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mojtaba","family":"Malek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faramarz","family":"Ismail-Beigi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farhad","family":"Zamani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masoudreza","family":"Sohrabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Reza babaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad E.","family":"Khamseh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,25]]},"reference":[{"issue":"6","key":"1498_CR1","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1002\/hep.20466","volume":"40","author":"JD Browning","year":"2004","unstructured":"Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004;40(6):1387\u201395.","journal-title":"Hepatology"},{"issue":"2","key":"1498_CR2","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1111\/j.1478-3231.2008.01790.x","volume":"29","author":"SM Alavian","year":"2009","unstructured":"Alavian SM, Mohammad-Alizadeh AH, Esna-Ashari F, Ardalan G, Hajarizadeh B. Non-alcoholic fatty liver disease prevalence among school-aged children and adolescents in Iran and its association with biochemical and anthropometric measures. Liver Int. 2009;29(2):159\u201363.","journal-title":"Liver Int"},{"issue":"14","key":"1498_CR3","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1056\/NEJMra0912063","volume":"363","author":"G Targher","year":"2010","unstructured":"Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med. 2010;363(14):1341\u201350.","journal-title":"N Engl J Med"},{"issue":"4","key":"1498_CR4","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/S2213-8587(18)30154-2","volume":"7","author":"N Stefan","year":"2019","unstructured":"Stefan N, H\u00e4ring H-U, Cusi K. Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies. Lancet Diabetes Endocrinol. 2019;7(4):313\u201324.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"1498_CR5","doi-asserted-by":"publisher","first-page":"18","DOI":"10.7570\/jomes.2019.28.1.18","volume":"28","author":"C-H Jung","year":"2019","unstructured":"Jung C-H, Mok J-O. The effects of hypoglycemic agents on non-alcoholic fatty liver disease: focused on sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists. J Obes Metab Syndr. 2019;28(1):18.","journal-title":"J Obes Metab Syndr"},{"issue":"2","key":"1498_CR6","doi-asserted-by":"publisher","first-page":"298","DOI":"10.2337\/dc19-0641","volume":"43","author":"S Kahl","year":"2020","unstructured":"Kahl S, Gancheva S, Stra\u00dfburger K, et al. Empagliflozin effectively lowers liver fat content in well-controlled type\u00a02 diabetes: a randomized, double-blind, phase 4, placebo-controlled trial. Diabetes Care. 2020;43(2):298\u2013305.","journal-title":"Diabetes Care"},{"issue":"11","key":"1498_CR7","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1007\/s11892-019-1266-7","volume":"19","author":"L Razavi-Nematollahi","year":"2019","unstructured":"Razavi-Nematollahi L, Ismail-Beigi F. Adverse effects of glycemia-lowering medications in type\u00a02 diabetes. Curr Diab Rep. 2019;19(11):132.","journal-title":"Curr Diab Rep"},{"key":"1498_CR8","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.2147\/DMSO.S212715","volume":"12","author":"NE Gharaibeh","year":"2019","unstructured":"Gharaibeh NE, Rahhal M-N, Rahimi L, Ismail-Beigi F. SGLT-2 inhibitors as promising therapeutics for non-alcoholic fatty liver disease: pathophysiology, clinical outcomes, and future directions. Diabetes Metab Syndr Obes Targets Ther. 2019;12:1001.","journal-title":"Diabetes Metab Syndr Obes Targets Ther"},{"issue":"8","key":"1498_CR9","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.2337\/dc18-0165","volume":"41","author":"MS Kuchay","year":"2018","unstructured":"Kuchay MS, Krishan S, Mishra SK, et al. Effect of empagliflozin on liver fat in patients with type\u00a02 diabetes and nonalcoholic fatty liver disease: a randomized controlled trial (E-LIFT Trial). Diabetes Care. 2018;41(8):1801\u20138.","journal-title":"Diabetes Care"},{"issue":"Supplement 1","key":"1498_CR10","doi-asserted-by":"publisher","first-page":"S14","DOI":"10.2337\/dc20-S002","volume":"43","author":"American Diabetes Association","year":"2020","unstructured":"American Diabetes Association. Classification and diagnosis of diabetes: standards of medical care in diabetes\u20142020. Diabetes Care. 2020;43(Supplement 1):S14\u2013S31.","journal-title":"Diabetes Care"},{"issue":"6","key":"1498_CR11","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1053\/j.gastro.2019.01.042","volume":"156","author":"PJ Eddowes","year":"2019","unstructured":"Eddowes PJ, Sasso M, Allison M, et al. Accuracy of FibroScan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease. Gastroenterology. 2019;156(6):1717\u201330.","journal-title":"Gastroenterology"},{"issue":"11","key":"1498_CR12","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1016\/j.ultrasmedbio.2010.07.005","volume":"36","author":"M Sasso","year":"2010","unstructured":"Sasso M, Beaugrand M, De Ledinghen V, et al. Controlled attenuation parameter (CAP): a novel VCTE\u2122 guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes. Ultrasound Med Biol. 2010;36(11):1825\u201335.","journal-title":"Ultrasound Med Biol"},{"issue":"4","key":"1498_CR13","doi-asserted-by":"publisher","first-page":"e0176027","DOI":"10.1371\/journal.pone.0176027","volume":"12","author":"Y-H Yen","year":"2017","unstructured":"Yen Y-H, Chen J-B, Cheng B-C, et al. Using controlled attenuation parameter combined with ultrasound to survey non-alcoholic fatty liver disease in hemodialysis patients: a prospective cohort study. PLoS One. 2017;12(4):e0176027.","journal-title":"PLoS One"},{"issue":"1","key":"1498_CR14","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s12933-016-0384-7","volume":"15","author":"R Bouchi","year":"2016","unstructured":"Bouchi R, Nakano Y, Ohara N, et al. Clinical relevance of dual-energy X-ray absorptiometry (DXA) as a simultaneous evaluation of fatty liver disease and atherosclerosis in patients with type\u00a02 diabetes. Cardiovasc Diabetol. 2016;15(1):64.","journal-title":"Cardiovasc Diabetol"},{"issue":"8","key":"1498_CR15","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1002\/hep4.1392","volume":"3","author":"JC Hsing","year":"2019","unstructured":"Hsing JC, Nguyen MH, Yang B, et al. Associations between body fat, muscle mass, and nonalcoholic fatty liver disease: a population-based study. Hepatol Commun. 2019;3(8):1061\u201372.","journal-title":"Hepatol Commun"},{"key":"1498_CR16","first-page":"75","volume":"8","author":"BA Banini","year":"2016","unstructured":"Banini BA, Sanyal AJ. Nonalcoholic fatty liver disease: epidemiology, pathogenesis, natural history, diagnosis, and current treatment options. Clin Med Insights Ther. 2016;8:75\u201384.","journal-title":"Clin Med Insights Ther"},{"key":"1498_CR17","unstructured":"The Oxford Center for Diabetes, Endocrinology and Metabolism. HOMA2 Calculator. Oxford: Diabetes Trial Unit; 2009."},{"key":"1498_CR18","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.pmedr.2016.03.003","volume":"3","author":"M Wanner","year":"2016","unstructured":"Wanner M, Probst-Hensch N, Kriemler S, Meier F, Autenrieth C, Martin BW. Validation of the long international physical activity questionnaire: influence of age and language region. Prevent Med Rep. 2016;3:250\u20136.","journal-title":"Prevent Med Rep"},{"issue":"1","key":"1498_CR19","doi-asserted-by":"publisher","first-page":"60","DOI":"10.3346\/jkms.2017.32.1.60","volume":"32","author":"Y-H Lee","year":"2017","unstructured":"Lee Y-H, Kim JH, Kim SR, et al. Lobeglitazone, a novel thiazolidinedione, improves non-alcoholic fatty liver disease in type\u00a02 diabetes: its efficacy and predictive factors related to responsiveness. J Korean Med Sci. 2017;32(1):60\u20139.","journal-title":"J Korean Med Sci"},{"issue":"2","key":"1498_CR20","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1111\/dom.13520","volume":"21","author":"M Shimizu","year":"2019","unstructured":"Shimizu M, Suzuki K, Kato K, et al. Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type\u00a02 diabetes and non-alcoholic fatty liver disease. Diabetes Obes Metab. 2019;21(2):285\u201392.","journal-title":"Diabetes Obes Metab"},{"key":"1498_CR21","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1007\/s10620-019-05573-y","volume":"65","author":"RS Khan","year":"2020","unstructured":"Khan RS, Newsome PN. Fat and fibrosis: does empagliflozin impair the progression of nonalcoholic steatohepatitis in patients with type\u00a02 diabetes mellitus? Dig Dis Sci. 2020;65:342\u20134.","journal-title":"Dig Dis Sci"},{"issue":"1","key":"1498_CR22","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1053\/j.gastro.2008.03.076","volume":"135","author":"L Huwart","year":"2008","unstructured":"Huwart L, Sempoux C, Vicaut E, et al. Magnetic resonance elastography for the noninvasive staging of liver fibrosis. Gastroenterology. 2008;135(1):32\u201340.","journal-title":"Gastroenterology"},{"issue":"2","key":"1498_CR23","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1111\/dom.13061","volume":"20","author":"T Shibuya","year":"2018","unstructured":"Shibuya T, Fushimi N, Kawai M, et al. Luseogliflozin improves liver fat deposition compared to metformin in type\u00a02 diabetes patients with non-alcoholic fatty liver disease: a prospective randomized controlled pilot study. Diabetes Obes Metab. 2018;20(2):438\u201342.","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"1498_CR24","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1507\/endocrj.EJ16-0295","volume":"64","author":"T Takase","year":"2017","unstructured":"Takase T, Nakamura A, Miyoshi H, Yamamoto C, Atsumi T. Amelioration of fatty liver index in patients with type\u00a02 diabetes on ipragliflozin: an association with glucose-lowering effects. Endocr J. 2017;64(3):363\u20137.","journal-title":"Endocr J"},{"issue":"1","key":"1498_CR25","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1007\/s00535-017-1364-8","volume":"53","author":"Y Seko","year":"2018","unstructured":"Seko Y, Sumida Y, Sasaki K, et al. Effects of canagliflozin, an SGLT2 inhibitor, on hepatic function in Japanese patients with type\u00a02 diabetes mellitus: pooled and subgroup analyses of clinical trials. J Gastroenterol. 2018;53(1):140\u201351.","journal-title":"J Gastroenterol"},{"issue":"6","key":"1498_CR26","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1210\/jc.2015-1966","volume":"100","author":"P Portillo-Sanchez","year":"2015","unstructured":"Portillo-Sanchez P, Bril F, Maximos M, et al. High prevalence of nonalcoholic fatty liver disease in patients with type\u00a02 diabetes mellitus and normal plasma aminotransferase levels. J Clin Endocrinol Metab. 2015;100(6):2231\u20138.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"1498_CR27","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1002\/hep.22429","volume":"48","author":"AL Fracanzani","year":"2008","unstructured":"Fracanzani AL, Valenti L, Bugianesi E, et al. Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes. Hepatology. 2008;48(3):792\u20138.","journal-title":"Hepatology"},{"issue":"5","key":"1498_CR28","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1002\/hep.27368","volume":"61","author":"M Ekstedt","year":"2015","unstructured":"Ekstedt M, Hagstr\u00f6m H, Nasr P, et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology. 2015;61(5):1547\u201354.","journal-title":"Hepatology"},{"issue":"2","key":"1498_CR29","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1007\/s10620-019-5477-1","volume":"65","author":"L-L Lai","year":"2020","unstructured":"Lai L-L, Vethakkan SR, Mustapha NRN, Mahadeva S, Chan W-K. Empagliflozin for the treatment of nonalcoholic steatohepatitis in patients with type\u00a02 diabetes mellitus. Dig Dis Sci. 2020;65(2):623\u201331.","journal-title":"Dig Dis Sci"},{"issue":"12","key":"1498_CR30","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1111\/liv.13481","volume":"37","author":"D Roulot","year":"2017","unstructured":"Roulot D, Roudot-Thoraval F, Nkontchou G, et al. Concomitant screening for liver fibrosis and steatosis in French type\u00a02 diabetic patients using Fibroscan. Liver Int. 2017;37(12):1897\u2013906.","journal-title":"Liver Int"},{"issue":"S1","key":"1498_CR31","doi-asserted-by":"publisher","first-page":"S99","DOI":"10.1002\/hep.20973","volume":"43","author":"GC Farrell","year":"2006","unstructured":"Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology. 2006;43(S1):S99\u2013S112.","journal-title":"Hepatology"},{"issue":"1","key":"1498_CR32","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.diabet.2015.10.003","volume":"42","author":"L Leiter","year":"2016","unstructured":"Leiter L, Forst T, Polidori D, Balis D, Xie J, Sha S. Effect of canagliflozin on liver function tests in patients with type\u00a02 diabetes. Diabetes Metab. 2016;42(1):25\u2013322.","journal-title":"Diabetes Metab"},{"issue":"9","key":"1498_CR33","doi-asserted-by":"publisher","first-page":"2784","DOI":"10.2337\/db16-0058","volume":"65","author":"SA Hawley","year":"2016","unstructured":"Hawley SA, Ford RJ, Smith BK, et al. The Na+\/glucose cotransporter inhibitor canagliflozin activates AMPK by inhibiting mitochondrial function and increasing cellular AMP levels. Diabetes. 2016;65(9):2784\u201394.","journal-title":"Diabetes"},{"key":"1498_CR34","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.diabres.2018.05.017","volume":"142","author":"N Kurinami","year":"2018","unstructured":"Kurinami N, Sugiyama S, Yoshida A, et al. Dapagliflozin significantly reduced liver fat accumulation associated with a decrease in abdominal subcutaneous fat in patients with inadequately controlled type\u00a02 diabetes mellitus. Diabetes Res Clin Pract. 2018;142:254\u201363.","journal-title":"Diabetes Res Clin Pract"},{"issue":"10","key":"1498_CR35","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.2337\/dc17-0518","volume":"40","author":"D Ito","year":"2017","unstructured":"Ito D, Shimizu S, Inoue K, et al. Comparison of ipragliflozin and pioglitazone effects on nonalcoholic fatty liver disease in patients with type\u00a02 diabetes: a randomized, 24-week, open-label, active-controlled trial. Diabetes Care. 2017;40(10):1364\u201372.","journal-title":"Diabetes Care"},{"issue":"1","key":"1498_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.14740\/jem632","volume":"10","author":"H Katsuyama","year":"2020","unstructured":"Katsuyama H, Hakoshima M, Iijima T, Adachi H, Yanai H. Effects of sodium-glucose cotransporter 2 inhibitors on hepatic fibrosis in patients with type\u00a02 diabetes: a chart-based analysis. J Endocrinol Metab. 2020;10(1):1\u20137.","journal-title":"J Endocrinol Metab"},{"issue":"14","key":"1498_CR37","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1080\/14656566.2017.1363888","volume":"18","author":"A Ohta","year":"2017","unstructured":"Ohta A, Kato H, Ishii S, et al. Ipragliflozin, a sodium glucose co-transporter 2 inhibitor, reduces intrahepatic lipid content and abdominal visceral fat volume in patients with type\u00a02 diabetes. Expert Opin Pharmacother. 2017;18(14):1433\u20138.","journal-title":"Expert Opin Pharmacother"},{"issue":"4","key":"1498_CR38","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1080\/00325481.2016.1169894","volume":"128","author":"L Blonde","year":"2016","unstructured":"Blonde L, Stenl\u00f6f K, Fung A, Xie J, Canovatchel W, Meininger G. Effects of canagliflozin on body weight and body composition in patients with type\u00a02 diabetes over 104 weeks. Postgrad Med. 2016;128(4):371\u201380.","journal-title":"Postgrad Med"},{"issue":"1","key":"1498_CR39","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1515\/med-2018-0059","volume":"13","author":"T Miyake","year":"2018","unstructured":"Miyake T, Yoshida S, Furukawa S, et al. Ipragliflozin ameliorates liver damage in non-alcoholic fatty liver disease. Open Med (Wars). 2018;13(1):402\u20139.","journal-title":"Open Med (Wars)"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-020-01498-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-020-01498-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-020-01498-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,24]],"date-time":"2021-09-24T23:41:21Z","timestamp":1632526881000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-020-01498-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,25]]},"references-count":39,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["1498"],"URL":"https:\/\/doi.org\/10.1007\/s12325-020-01498-5","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,25]]},"assertion":[{"value":"14 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}